The promoter regions of genes that are differentially regulated in the synovial membrane during the course of rheumatoid arthritis (RA) represent attractive candidates for application in transcriptionally targeted gene therapy. In this study, we applied an unbiased computational approach to define proximal-promoters from a gene expression profiling study of murine experimental arthritis. Synovium expression profiles from progressing stages of collagen-induced arthritis (CIA) were classified into six distinct groups using k-means clustering. Using an algorithm based on local over-representation and comparative genomics, we identified putatively functional transcription factor-binding sites (TFBS) in TATA-dependent proximalpromoters. Applying a filter based on spacing between TATA box and transcription start site (TSS) combined with the presence of over-represented nuclear factor κB (NFκB), AP-1, or CCAAT/enhancer-binding protein β (C/ EBPβ) sites, 382 candidate murine and human promoters were reduced to 66, corresponding to 45 genes. In vitro, 9 out of 10 computationally defined promoter regions conferred cytokine-inducible expression in murine cells and human synovial fibroblasts. Under these conditions, the serum amyloid A3 (Saa3) promoter showed the strongest transcriptional induction and strength. We applied this promoter for driving therapeutically efficacious levels of the interleukin-1 receptor antagonist (Il1rn) in a diseaseregulated fashion. These results demonstrate the value of bioinformatics for guiding the selection of endogenous promoters for transcriptionally targeted gene therapy.
IntroductIon
Selective spatial and temporal expression of a therapeutic trans gene has a major impact on the safety and efficacy of gene thera peutic treatments for human disease. This can be accomplished by transcriptional targeting using endogenous or synthetic cisregulatory DNA regions, which facilitate tissue/cellspecific or physiologically regulated expression. Predominantly in cancer gene therapy, numerous tumor/tissuespecific or drug/radiation inducible promoters have been developed and applied. 1 With emphasis on the discontinuous clinical course of rheu matoid arthritis (RA), which is characterized by spontaneous remissions and exacerbations of joint inflammation, transcrip tionally targeted gene therapy appears ideally suited. The few endogenous promoters that have been tested in RA thus far were empirically derived. Efficacious inflammationresponsive expres sion in experimental arthritis has been accomplished using the promoter elements of the murine acutephase response gene complement factor 3 (C3) (refs. 2,3) and the human cytokine gene interleukin6 (IL6) (ref. 4) . Although IL6 and C3 promoters showed high specificity toward inflammation, they only conferred weak transcriptional activity that had to be enhanced artificially using an interleukin1 enhancer region 5 or a recombinant human immunodeficiency virus1tat transcriptional activator, 6 respec tively. However, the application of the latter approach is hampered due to the immunogenic properties of human immunodeficiency virus1 tat.
The promoter of a gene is defined as the cisregulatory DNA region that drives transcription in response to environmental sig nals. Roughly, a promoter can be divided into a core, proximal, and distalpromoter region. The corepromoter encompasses the 80-100 base pair (bp) region surrounding the transcription start site (TSS) and is required for assembly of the preinitiation com plex. 7 Bioinformatic analyses of mammalian core promoters have revealed that the spacing between the TATA box and TSS affects the transcriptional specificity of the downstream transcript, and the highest specificity has been observed for TATATSS distances between −32 and − 29 (ref. 8) . In mouse, the most common TATA TSS spacings are 30 and 31 bp (ref. 9) , and most functional TATA boxes reside in a window ranging from positions −34 to −27 rela tive to the TSS. 8 The proximalpromoter (−500/+200 relative to the TSS) contains modules of transcription factor-binding sites (TFBS) that confer tissue and contextspecific expression. 10 Several bioinformatics tools have been developed for computational iden tification of these TFBS in eukaryotic promoters (reviewed in ref. 11 ). The accuracy of prediction of TFBS that are functional in vivo has been significantly enhanced using the combination of phylogenetic footprinting with sets of coregulated genes. 12 These methods have been used to successfully identify cartilage 13 or musclespecific 14 cisregulatory elements in mammals.
In this study, we computationally designed and verified endogenous proximal promoters from a gene expression profil ing study of murine collageninduced arthritis (CIA) for tran scriptionally targeted gene therapy for RA. The 201 genes that were significantly regulated during advancing CIA severity stages were divided in clusters of distinct expression profiles using k-means clustering. Next, overrepresented TFBS per cluster were calculated in proximalpromoter sequences of the genes and their human orthologs that contained a putative TATA box within the −44 to −17 bp region relative to the TSS. We investigated the tran scriptional properties of 10 computationally identified proximal promoter regions in vitro using lentiviral luciferase reporters. Nine out of ten promoters drove gene expression in a cytokine inducible fashion. The serum amyloid A3 (Saa3) proximalpromoter con ferred high transcriptional specificity and activity toward inflam mation, and we demonstrated that this promoter improved the efficacy of transcriptionally targeted adenoviral gene therapy using interleukin1 receptor antagonist (Il1rn) as a transgene.
results

K-means clustering of cIA gene expression profiles
In local gene therapy for RA, the synovial tissue (which is) a thin layer of connective tissue consisting of fibroblast and macrophagelike cells is transduced by viral vectors. 15 To elucidate candidate genes whose proximalpromoter might confer inflammationinducible expression, we analyzed gene expression profiles in inflamed syn ovium of mice with CIA. Whole genome expression profiles were obtained from synovial tissue biopsies of knee joints from both naive and DBA/1J mice at day 30 of CIA using the Mouse Genome 430 2.0 array (Figure 1a ). Prior to isolation, we semiquantitatively scored the degree of joint inflammation and subdivided samples in four advancing stages of disease severity (Figure 1b) . For each stage, hybridization experiments were performed in triplicate and data normalized using MAS 5.0 software. Using EXPANDER 4.1 software, 16 we obtained 234 Affymetrix probes that correspond to 201 unique Ensembl genes whose expression was at least tenfold upregulated in at least three severity stages compared to naive con ditions. Next, the standardized (mean 0 and variance 1) expression profiles were partitioned into distinct clusters using the kmeans algorithm. Partitioning into six clusters resulted in the most opti mal average separation (0.913) and homogeneity (0.938) of clus ters. The average standardized expression levels of the clusters are plotted in Figure 1c . The annotation of the probe identities per cluster is documented in Supplementary Table S1 .
AP-1, c/eBPβ, and nF-κB-binding sites are over-represented in tAtA proximal-promoters
To filter for promoters with high transcriptional specificity toward inflammation, we analyzed the murine and human orthologous proximalpromoters (−500/+200 region) for the presence of a putative TATA box within a −44 to −17 bp window relative to the TSS. The promoter sequences of 191 murine and human orthologs ( Supplementary Table S2 ) were retrieved from the Cold Spring Harbor Promoter database, 17 and putative TATA box-binding sites were searched with the program PATSER 18 using TATA_01 (M00252) and TBP_01 (M00471) position weight matrices (PWMs) in the TRANSFAC 7.0 (ref. 19) database. For 37 genes, a putative TATA box was predicted in both murine and human promoter sequences. Additionally, a single TATA TFBS was predicted in promoter sequences of 21 murine and 12 human genes ( Table 1 ). The TATA proximalpromoters were used for subsequent identification of over represented cisregulatory ele ments. For this, we used Transcription Factor MatrixExplorer software because it combines motif over representation with comparative genomics and takes spatial conservation of cis regulatory elements into account. Per cluster, overrepresented TFBS were searched using PWMs corresponding to human or mousebinding factors in the public TRANSFAC and JASPAR 20 databases. Proximalpromoters from clusters 1 and 2 were Gene Pos a score b ortholog Pos score significantly (P < 10 −6 ) enriched for PWMs corresponding to the transcription factor Rel/nuclear factor κB (NFκB). In clus ters 2, 4, 5, and 6, several PWMs for the transcription factor activator protein1 (AP1) were overrepresented. In contrast, promoters of cluster 5/6 genes, whose transcriptional activity correlates most closely with disease severity, were enriched for CCAAT/enhancerbinding protein β (C/EBPβ) binding sites. The majority of overrepresented cisregulatory elements were spatially conserved in a narrow 200-100 bp window upstream (NFκB −170/−50, AP1 −290/−30, and C/EBPβ -240/−45) of the putative TATA box-binding site ( Table 2) . Target genes of these transcription factors were identified using PATSER with high quality TRANSFAC PWMs, compiled from >20 experimentally verified binding sites, NFκB65_01 (M00052), AP1_01 (M00517), and CEBPB_01 (M00109). Bona fide hits (P < 10 −8 ) were ranked according to the log ratio of their p values (ln p) ( Table 3) . From the 97 TATAdependent promoters, 66 contained a spatially conserved NFκB, AP1, or C/EBPβ TFBS. Without taking spatial conservation into account, 81 promoters contained a putative binding site. This strategy has narrowed down the num ber of candidate proximalpromoters for transcriptional targeting in arthritis and provides useful information for rational selection of the promoter region.
construction and validation of transcriptionally targeted sIn lentiviral vectors
We developed 10 transcriptionally targeted lentiviral vectors, in which the firefly (Photinus Pyralis) luciferase complementary DNA (cDNA) expression is under control of computationally identi fied proximalpromoters. All promoters comprised the upstream region containing the identified overrepresented TFBS, the TSS, and a part of the 5′ UTRexon (Figure 2) . To evaluate the basal transcriptional activity of the cloned promoter regions, murine NIH3T3 fibroblasts were cotransfected with promoter constructs and as internal control reporter pRLTK encoding constitutively active Renilla Reniformis luciferase. Cells were transfected with a promoterless or constitutively active cytomegalovirus immediate early (CMV) promoter construct as negative and positive control, respectively. Assessment of the relative luciferase activity at 2 days after transfection revealed that the basal transcriptional activity of all generated constructs was approximately three to tenfold lower than obtained with the CMV promoter ( (Table 1 ) and the majority of over represented TFBS were conserved between species (Table 3) , we investigated whether the murine promoters would be responsive in synovial fibroblasts isolated from RA patients (RASF). Primary synovial fibroblasts (n = 4) were transduced with lentiviral vec tors containing the Saa3, Cxcl1, Cxcl5, or Mmp13 promoter. Two days after transduction, RASF were stimulated for 24 hours with either recombinant human IL1β (0.25 ng/ml) or hTNFα (1 ng/ml) alone, or the combination of the two cytokines (Figure 3d) . The Saa3 promoter activity was most strongly induced by stimulation with hIL1β (17 ± 2) or hTNFα (15 ± 2), and the induction was less than additive for the combination of stimuli (22 ± 3). As in murine fibroblasts, the Cxcl5 and Mmp13 were modestly and non responsive, respectively. Strikingly, the Cxcl1 promoter activity was induced by hIL1β (4.0 ± 0.3) but only marginally by hTNFα (1.6 ± 0.2), whereas the combination of cytokines synergistically activated the Cxcl1 promoter (7.0 ± 0.8).
Saa3 promoter drives therapeutically efficacious
Il1rn in a disease-regulated fashion Previously, we have demonstrated therapeutic efficacy of tran scriptionally targeted IL4 gene therapy in CIA using a hybrid pro moter consisting of the enhancer region of IL1B (−3690/−2720) fused to the proximal promoter of IL6 (−163/+12) (IL1E/IL6P). 4 However, when the IL4 cDNA was replaced for the Il1rn cDNA, we failed to prevent the development and progression of CIA (data not shown) as described for constitutive overexpression of this transgene. 2, 21 We sought to address this efficacy issue by substituting the IL1E/IL6P promoter for a computationally identi fied promoter. Based on in vitro validations of promoter strength and responsiveness (Figure 3) , the Saa3 promoter was selected as the most promising candidate for such a substitution. First, we compared the promoter strength under arthritic conditions in vivo. Knee joints of C57Bl/6 mice were transduced by lenti viral vectors, and after 7 days, an acute arthritis was induced by intraarticular injection of zymosan A (180 µg). Twentyfour hours after challenge, we assessed luciferase activity ex vivo (Figure 4a) . To control for amplification of transgene expression by inflammationinduced proliferation of lentivirally transduced synovium, 22 knee joints were transduced with a vector encoding Protein levels for IL1E/IL6Pdriven Il1rn were around the detec tion limit of the enzymelinked immunosorbent assay (ELISA) (1 ng/ml). Next, we tested therapeutic efficacy of these vectors in an in vitro assay system (Figure 4b) . NIH3T3 fibroblasts stably transfected with the luciferase gene downstream of five tandem repeats of NFκBbinding sites were transduced (MOI 10) at day 1 with adenovirus encoding transcriptionally targeted Il1rn and at day 2 with constitutively expressed Il1b. As a positive and negative control, cells were transduced at day 1 with adenovirus encod ing constitutively expressed Il1rn (CMV) or nonencoding adeno virus (del). At day 3, we assessed Il1rn protein levels by ELISA and IL1βinduced NFκB activation by luciferase assay at day 3. As expected, CMVdriven Il1rn expression (56.8 ± 11.8 ng/ ml) completely suppressed IL1βinduced NFκB activation (P < 0.01). Empty control virus and IL1E/IL6Pdriven Il1rn expression (undetectable) failed to significantly inhibit NFκB activation. In contrast, Saa3driven Il1rn expression (11.1 ± 1.7 ng/ml) led to a significant (P < 0.01) reduction (~56%) of IL1βinduced NFκB activation. These results indicate that the promoter strength and responsiveness of Saa3 might be sufficient to provide therapeuti cally efficacious protein levels in a transcriptionally targeted Il1rn gene therapy approach for experimental arthritis.
dIscussIon
Endogenous proximalpromoters that confer a range of transcrip tional activities in an inflammationspecific fashion are of great value toward tailormade transcriptionally targeted gene therapy for RA. To this end, we used a gene expression profiling study of Saa3
T a n f a ip CIA for elucidating diseaseregulated genes and performed com putational analyses on the proximalpromoter regions to define DNA regulatory elements that can be applied for transcriptional targeting. Using this approach, we narrowed down the number of candidate murine and human promoters from 382 to 66, cor responding to 45 unique genes. In our approach, we took the spacing between TATA box and TSS as a filtering parameter for transcriptional specificity. The rationale for this was derived from recent studies 8, 9 showing the association of TATAdependent transcription with tissue/context specific gene expression. Moreover, these studies demonstrate that the TATATSS spacing affects the transcriptional specificity of the downstream transcript. We predicted putative bona fide TATA boxes in using matching of PWM models. Generally, the score of a predictive PWM model is highly correlated with the strength of the protein-DNA interaction. 23 However, a genomewide charac terization of the interaction between the TATA box and the pre initiation complex has revealed the absence of a global correlation between PWM score and tissue specificity. 8 These findings are reflected in our computations in which we could not establish any correlation between PWM score and spacing. Accordingly, in the experimental verifications using promoterluciferase constructs, we did neither find an apparent correlation between TATA box scores and basal promoter activity in a murine fibroblast cell line.
Apart from the TATATSS spacing, the identification of putative TFs that govern a particular expression profile was the second key determinant for selection of promoter regions. As demonstrated in similar approaches, 13, 14 the combination of coregulated genes with phylogenetic footprinting proved fruitful for identification of over represented TFBS. Supporting evidence for the functional rele vance of the predicted overrepresented TFBSs in RA is substantial. The overrepresentation of NFκB and AP1binding sites corre spond to the pivotal role that has been implied for these factors in human RA, CIA, and immunity. [24] [25] [26] [27] Enhanced expression and DNAbinding activity of C/EBPβ in synovial tissue of RA patients has been implicated in the pathology 28 and chronicity 29 of disease. The latter coincides with the enrichment of C/EBPβbinding sites in the CIA clusters in which the gene expression profile was closely correlated with disease severity. The additional enrichment of Spi1 (Pu.1) and C/EBPα binding sites in cluster 6 is expected to arise from the increasing infiltration of the inflamed joint in CIA by myeloid (monocytes, dendritic cells, and neutrophils) and lym phoid (T and B cells) cells. Pu.1 and C/EBPα are key factors in development of myeloid and B cells. 30 Interestingly, promoters of myeloid and Bcellspecific genes often contain a regulatory mod ule consisting of a C/EBPα motif in close proximity (<60 bp) of the Pu.1 motif. 31 Indeed, the conserved locations of Pu.1 (−273/−66) and C/EBPα (−282/−78) in our analyses indicate the presence of such myeloidspecific modules. Because synovial fibroblasts repre sent the target cells for local gene therapy, 15, 32 the identification of myeloidspecific modules might be exploited to further refine the number of candidate promoters. Besides aforementioned TFs, we expect a contribution of the TF signal transducers and activators of transcription1/3 (STAT1/3) (ref. 33) , and interferon regula tory factor1 (ref. 34 ) in synovial inflammation. Indeed, scanning TATAdependent promoters with corresponding PWMs (STAT_01 and IRF1_01), we found 15 and 36 promoters with a putative bind ing site, respectively (data not shown). However, these hits were evenly dispersed over the clusters on a wide range (−500/−100) of positions, which explains the absence of overrepresentation for these TFBS in our analyses. The accuracy of the approach for infer ring functional cisregulatory elements is not only demonstrated by our experimental verifications but also by literature confirming the functionality of computationally identified topranking TFBS in several promoters such as Il1b, 35 The strength of our approach lies in the combination of gene expression profiling for identification of candidate genes with com putational prediction of functional endogenous proximal promot ers. These are expected to contain evolutionarily conserved optimal combinations of and spacings between TFBSs. This represents a major advantage over recent efforts that aim at tailoring gene expression using genetic engineering of synthetic promoters. 25, 39, 40 Although these studies have demonstrated encouraging results for modulating transgene expression in prokaryotes, the extrapo lation to eukaryotic transcriptional regulation by modules proves far more complex and the screening of hundreds of randomly assembled synthetic promoters is laborious and timeconsuming. Still, the identified overrepresented TFBS and their distance con straints might be useful for guiding the rational design of a syn thetic promoter. For example, it was demonstrated for RA gene therapy that a synthetic promoter consisting of six tandem repeats of NFκB consensus sites drives efficacious 41 expression of anti TNFα. The functionality of this promoter might be explained by the fact that the construct consists of a TFBS that is overrepre sented in inflammationinduced genes and positioned within the evolutionary conserved −170/−50 region upstream of the TSS. The pitfall of using Il1rn as a transgene lies in the fact that it needs to be present in at least 100fold molar excess in order to block the effects of IL1β on synoviocytes and chondrocytes. 42 However, using Saa3driven Il1rn expression, we obtained >50% inhibition of an CMVdriven, exaggerated, and nonphysio logical amount of IL1β. The relatively high transcriptional strength of the Saa3 proximal promoter has been demonstrated by Varley and coworkers. 43 In their study, Saa3driven luciferase expression exceeded that of the CMV promoter in response to cytokinerich conditioned medium prepared from the culture supernatant of lipopolysaccharide stimulated human peripheral blood mono cytes. In combination with our computational analyses and verifications, the Saa3 promoter is the most appropriate endog enous promoter for transcriptionally targeted Il1rn gene therapy for arthritis.
For the panel of inflammationresponsive promoters, we envis age two major applications. First, these promoters can be applied in noninvasive imaging approaches of joint inflammation or acti vation of particular transcription factors, e.g., AP1 (Mmp13) ver sus NFκB (Cxcl1), in human and experimental arthritis. Whether these proximal promoters confer differential expression patterns during experimental arthritis will be investigated using an in vivo imaging approach. Second, differential transcriptional activities can be exploited for gene therapy tailored to transgene properties, e.g., a promoter with strong transcriptional activity for generating the required excess of Il1rn expression and a promoter with low basal activity for minimizing Il4induced side effects.
MAterIAls And Methods
Animals. Male 10-12weekold DBA/1J mice were obtained from Janvier (Le GenestSaintIsle, France). C57Bl/6 mice were obtained from Charles River Laboratories (Sulzfeld, Germany). During viral experiments, mice were housed in lowpressure isolator cages. The animals were fed a stan dard diet with food and water ad libitum. All in vivo studies complied with national legislation and were approved by the local authorities of the Care and Use of Animals.
Induction of CIA.
Bovine collagen type II (bCII) was dissolved in 0.05 mol/l acetic acid to a concentration of 2 mg/ml and was emulsi fied in equal volumes of Freund's complete adjuvant (2 mg/ml of Mycobacterium tuberculosis strain H37Ra; Becton Dickinson, Detroit, MI). DBA1/J mice were immunized intradermally at the base of the tail with 100 µl of emulsion (100 µg of bCII). On day 21, the mice were given an intraperitoneal booster injection of 100 µg bCII dissolved in phosphatebuffered saline (PBS). Mice were sacrificed on day 30 by cer vical dislocation. Prior to biopsy, knee joints were scored visually using four grades: nondiseased, mild (minor swelling and color change due to infiltration), moderate (marked swelling), and severe (severe swelling and patellar tendon structure not visible). Synovial tissue samples from the lateral and medial sites (n = 24, 12 knee joints per severity stage) were isolated in a standardized manner using a 3 mm biopsy punch (Stiefel, Wächtersbach, Germany), as described previously. 44 Samples were pooled in a randomized fashion to generate triplicates consisting of eight biopsies.
RNA isolation. Total RNA from biopsy punches was prepared by TRIzol extraction (Invitrogen Life Technologies, Carlsbad, CA), and purified on an affinity resin (RNeasy Kit; Qiagen, Hilden, Germany) according to the manufacturer's instructions. Quantity and purity were assessed by the absorbance at λ = 260 nm (A 260nm ), and the ratio A 260nm /A 280nm . Integrity of the RNA was confirmed by nondenaturing agarose gel electrophoresis. Total RNA was stored at −80 °C until further processing.
Oligonucleotide array. One microgram of total RNA was used as a start ing material for cDNA preparation. Generation of biotinylated cRNA and subsequent hybridization, washing and staining of MOE 430_2 oligonucle otide arrays (Affymetrix, Santa Clara, CA) were performed according to the Affymetrix Expression Analysis Technical Manual for onecycle ampli fication. The arrays were then scanned using a laser scanner GeneChip Scanner (Affymetrix), and data were analyzed and normalized using Affymetrix Microarray Suite (MAS) 5.0 software according to the manu facturer's instruction. The gene expression data were deposited in the Gene Expression Omnibus database under accession number GSE13071.
Cluster analysis. Filtering, standardization, and cluster analysis were per formed using Expression Analyzer and Displayer (EXPANDER) software version 4.1 (ref. 16 ). The mean (n = 3) expression values calculated from the normalized microarray data using Excel served as input. After filtering for tenfold regulated probes, the expression values were standardized using the mean 0 and variance 1 algorithm. Cluster analyses were performed using k-means clustering with the number of clusters set to six.
Promoter sequence retrieval. Affymetrix probe identifiers were con verted into Ensembl gene identifiers (National Center for Biotechnology Information m37 mouse assembly) and RefSeq DNA identifiers (mm8) using BioMart (http://www.biomart.org). Human orthologs were retrieved from the Mouse Genome Database. 45 We extracted the proximal promoter regions of these genes (−500/+200) from the Cold Spring Harbor Laboratory mammalian promoter database 17 using RefSeq identifiers. When multiple promoters existed for a gene, we selected either a promoter from the Eukaryotic Promoter Database or Database of Transcription Start Sites. When the prior two were unavailable, we selected the promoter with the shortest distance to the gene.
Identification of TFBS.
The PATSER program 18 at the Regulatory Sequence Analysis Tools server (http://rsat.ulb.ac.be/rsat) 46 was used to search position weight matrix models collected from the public TRANSFAC 7.0 database. 19 Both strands of the promoter sequences were scanned in our analyses. Sequences with scores higher than the cutoff calculated by PATSER were considered as putative TFBS. 47
Identification of over-represented TFBS.
Promoter sequences with a putative TATAbinding site were scanned, per cluster, for 322 vertebrate matrices from the TRANSFAC 7.0 and JASPAR 20 databases using TFM Explorer (http://bioinfo.lifl.fr/TFME). 12 The ratio parameter, indicating the minimal average density of hits in the cluster relative to the reference model, was set to 4.0. PWMs with a P value < 10 −6 were regarded as sig nificantly overrepresented. Promoter Design for Transcriptional Targeting in RA use of the thirdgeneration selfinactivating (SIN) transfer vectors pRLL cPPTPGKmcsPRESIN containing the human phosphoglycerate kinase (PGK) promoter and the promoterless pRLLcPPTmcsPRESIN (kind gift from J. Seppen, AMC Liver Center, Amsterdam, the Netherlands). For clon ing, we used Pfu DNA polymerase (Stratagene, La Jolla, CA) and T4 DNA Ligase (New England Biolabs, Ipswich, MA). All generated constructs were verified by sequencing. The firefly luciferase cDNA from pGL3b (Promega) was transferred as an NheI/XbaI fragment into the multiple cloning site generating pRLLcPPTPGKLucPRESIN and pRLLcPPTLucPRE SIN. The plasmid pRLLcPPTCMVLucPreSIN was generated by PCR cloning the CMV promoter from pShuttleCMV (Stratagene) into SalI/ HpaI sites using primers FW 5′ GTCGACTAGTAATCAATTACGGGG3′ and RV 5′GTTAACGGATCTGACGGTTCAC3′. The murine promoter sequences were PCR cloned from liver genomic DNA into SalI/NheI sites of pRLLcPPTmcsLucPRESIN using primers in Supplementary Table S3 . The IL1E/IL6P promoter was transferred as a SalI/NheI fragment from pGL3IL1E/IL6P 5 into pRLLcPPTmcsLucPRESIN. The cDNA of the mouse Il1rn gene was transferred as a SalI/XbaI fragment from pShuttle CMVIl1rn 48 into pRLLcPPTPGKmcsPRESIN. For constructing pRLLcPPTSaa3Il1rnPRESIN, Il1rn was amplified from pShuttleCMV Il1rn using primers FW 5′GCTAGCGCCACCATGGAAATCTGCTGGG GAC3′ and RV 5′TCTAGACTATTGGTCTTCCTGGAAG3′ introduc ing a 5′ NheI and 3′ XbaI site, and blunt ligated into the SrfI site of pCR Script Amp SK(+) (Stratagene). The luciferase cDNA was removed from pRLLcPPTSaa3LucPRESIN by restriction with NheI/NsiI and religated with a NheI/PstI fragment from pPCRScriptIl1rn (−). A SalI/XbaI frag ment from pRLLcPPTSaa3Il1rnPRESIN containing the Saa3 promoter and Il1rn cDNA was transferred to pShuttlepolyA to give pShuttleSaa3 Il1rnpolyA. The cDNA of mouse interleukin1 β (Il1b) was PCR cloned from reverse transcribed C57Bl/6 synovial tissue RNA into the KpnI/XhoI sites of pShuttleCMV using primers FW 5′AAAGGTACCGCTATGGCA ACTGTTCC3′ and RV 5′TTTCTCGAGTTAGGAAGACAC3′.
Lentiviral vector production. Packaging of VSVG pseudotyped recom binant lentiviruses was performed by transient transfection of 293T cells.
The day prior to transfection, 293T cells were seeded in a T75 flask at 1 × 10 5 cells/cm 2 in DMEM supplemented with 10% FCS, 1 mmol/l pyruvate, 40 µg/ml gentamicin, and 0.01 mmol/l watersoluble cholesterol (Sigma, St Louis, MO). Cells were cotransfected with 19 µg transfer vector, 14 µg gag/pol packaging plasmid (pMDLg/pRRE), 4.7 µg rev expression plas mid (RSVREV), and 6.7 µg VSVG expression plasmid (pHITG) by calcium phosphate precipitation. Transfections were performed in 6 ml DMEM without antibiotics and cholesterol, and proceeded for 16 hours. Thereafter, medium was replaced with fully supplemented DMEM and supernatant harvested after 24 and 48 hours. Cell debris was removed by centrifugation at 1,500 rpm for 5 minutes at 4 °C, followed by pas sage through a 0.45 µm pore polyvinylidene fluoride Durapore filter (Millipore, Bedford, MA). For concentration by ultracentrifugation, 28 ml supernatant was layered on 4 ml 20% sucrose solution and cen trifuged at 25,000 rpm in a Surespin 630 rotor (Sorvall; Thermo Fisher Scientific, Waltham, MA). Pelleted viruses were resuspended in sterile PBS and stored at −80 °C. Viral titers were determined by assaying p24 gag values with a commercial ELISA kit (Abbott Diagnostics, Hoofddorp, The Netherlands) and expressed as ng p24 gag /µl.
Adenoviral vectors. Replicationdeficient adenoviral vectors (E1/E3
deleted) Ad5.Saa3Il1rn, Ad5.IL1E/IL6PIl1rn, Ad5.CMVIl1rn, Ad5. CMVIl1b, and Ad5.del were prepared according to the AdEasy system (Stratagene), with the exception that replicationcompetent recombinant free viral particles were produced in E1 transformed N52E6 amniocyte cells. 49 Viruses were purified by two consecutive CsCl 2 gradient purifica tions and stored in small aliquots at −80 °C in buffer containing 25 mmol/l Tris, pH 8.0, 5 mmol/l KCl, 0.2 mmol/l MgCl 2 , 137 mmol/l NaCl, 730 µmol/l Na 2 HPO 4 , 0.1% (wt/vol) ovalbumin, and 10% (vol/vol) glycerol. The infectious particle titer (focusforming units) was determined by titrat ing vector stocks on 911 indicator cells and measuring viral capsid protein immunohistochemically 20 hours after transduction.
Luciferase measurements.
For in vitro reporter studies, cells were seeded at 5 × 10 4 cells per well in a Krystal 2000 96well plate (Thermo Fisher Scientific). The day after, cells were transduced with 50 ng p24 gag equivalent lentivirus in 50 µl medium supplemented with 8 µg/ml polybrene (Sigma) for 4 hours at 37 °C. Cells were serumstarved (1% FCS) for 2 days and subsequently stimulated with recombinant human IL1β (R&D Systems Europe, Oxford, UK), TNFα (Abcam, Cambridge, UK), or E. Coli lipopoly saccharide (Sigma) for indicated hours and subsequently lysed in icecold lysis buffer (0.5% NP40, 1 mmol/l DTT, 1 mmol/l EDTA, 5 mmol/l MgCl 2 , 100 mmol/l KCl, and 10 mmol/l TrisHCl pH 7.5). Luciferase activity was quantified using the BrightGlo luciferase assay system (Promega) by add ing an equal volume of BrightGlo to the cell lysate. Luminescence was quantified in a luminometer (LUMIstar; BMG, Offenburg, Germany), expressed as relative light units and normalized to total protein content of the cell/tissue extracts. For transient transfection experiments, cells were seeded at 70% confluency in a 24well plate and cotransfected with 500 ng firefly luciferase reporter and 50 ng Renilla luciferase reporter (pRLTK) using ArrestIn (Open Biosystems, Huntsville, AL) according to the manu facturer's instructions. Cells were serumstarved (1% FCS) for 2 days, and firefly and Renilla luciferase activities were quantified using the Dual Luciferase Reporter Assay System (Promega). For in vivo studies, knee joints were injected with 300 ng p24 gag equivalent lentivirus in a total vol ume of 6 µl. Seven days after transduction, knee joints were injected with 180 µg zymosan A/6 µl PBS (Sigma). After 1 day, patellae with surrounding tissue were dissected, put in 250 µl cell culture lysis buffer (Promega) and snap frozen in liquid nitrogen. Supernatant was centrifuged at 13,000 rpm for 5 minutes and luciferase activity assayed as described above.
In vitro Il1rn-efficacy assay system. NIH3T3 fibroblasts stably transfected with a 5xNFκB luciferase reporter were seeded at 5 × 10 4 cells per well in a Krystal 2000 96well plate. The day thereafter, cells were transduced at an MOI of 10 with Il1rnencoding or control nonencoding adeno virus (Ad5.del) in DMEM for 4 hours at 37 °C. After 24 hours, medium was aspi rated, cells were rinsed and transduced at an MOI of 10 with Il1bencoding or Ad5.del virus in DMEM for 4 hours at 37 °C. The day after the second transduction, IL1βinduced NFκB activation was measured by assessing the luciferase activity as described above.
Il1rn ELISA. White highbinding flat bottom 96well plates (Greiner Bio One, Alphen a/d Rijn, the Netherlands) were coated with the capture anti body rat antimurine Il1rn (MAB480; R&D Systems, Minneapolis, MN) at 3 µg/ml in 0.1 mol/l carbonate buffer pH 9.6 and incubated overnight at 4 °C. Nonspecific binding sites were blocked with 1% bovine serum albumin in PBS for 1 hour at room temperature. Between subsequent incubations, wells were rinsed three times with 0.1% Tween20 in PBS. Twentyfour hour culture supernatants (100 µl) from 3 × 10 5 HeLa cells transduced with adenoviral Il1rnexpressing vectors at an MOI of 10 were added to coated wells and incubated for 3 hours at room temperature. The plates were then incubated with the biotinylated goat antimurine Il1rn (BAF 480; R&D Systems) at 0.2 µg/ml in 0.1% bovine serum albumin/ PBS for 2 hours, followed by a 30minute incubation with streptavidin conjugated horseradish peroxidase (Dako, Glostrup, Denmark) at 0.25 µg/ ml in PBS. Antibody complexes were detected by incubation with the SuperSignal ELISA Pico Chemiluminescent Substrate (Pierce, Rockford, IL) and luminescence quantified in a luminometer.
Statistics. Data are represented as means ± SEM, and significant differences were calculated using oneway analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test (GraphPad Prism, San Diego, CA). P values < 0.05 were regarded significant. suPPleMentAry MAterIAl Table S1 . Annotation of the probe identities per k-means cluster. Table S2 . Proximal (−500/+200) promoter sequences used in this study. Table S3 . Supplementary Methods: Primers.
